Abstract
Several options are available today in the treatment of advanced colorectal cancer: traditional chemotherapeutic regimens, targeted therapies, and their combinations. Panitumumab is a new, fully human anti-EGFR monoclonal antibody, what is well-tolerated, effective as a single agent in chemotherapy refractory patients and in different combinations. The clinical response is restricted to tumors with wild-type RAS, therefore the RAS status should be checked before treatment.
Similar content being viewed by others
References
Foon KA, Yang XD, Weiner LM et al (2004) Preclinical and clinical evaluation of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58:984–990
Jakobovits A, Amado RG, Yang X et al (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25:1134–1143
Freeman D, McDorman K, Bussh T et al (2004) Mono and combination-therapeutic activity of panitumumab (ABX-EGF) on human A431 epidermoid and HT-29 colon carcinoma xenografts: correlation with pharmacodynamic parameters. Proc Am Assoc Cancer Res 27–31
Lopez-Albaitero A, Ferris RL (2007) Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngeal Head Neck Surg 133:1277–1281
Siena S, Sartore-Bianchi A, Di Nicolantonio F et al (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308–1324
Barault L, Veyrie N, Jooste V et al (2008) Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colonic cancer. Int J Cancer 122:2255–2259
Artale S, Sartore-Bianchi A, Veronese S et al (2008) Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26:4217–4219
Andreyev HJ, Norman AR, Cunningham D et al (2001) Kirsten ras mutation in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 85:692–696
Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared to best supportive care alone in patients with chemotherapy-refractory a metastatic colorectal cancer. J Clin Oncol 25:1658–1664
Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634
Roth A, Tejpar S, Yan P et al (2009) Correlation of molecular markers in colon cancer with stage-specific prognosis: results of the translational study on the PETACC 3-EORTC 40093-SAKK 60-00 trial. ASCO, Gastrointestinal cancers Symposium, San Francisco, abstract 288
Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279–286
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648
Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995
Monzon FA, Ogino S, Hammond EH et al (2009) The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 133:1600–1606
Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712
Sartore-Bianchi A, Martini M, Molinari F et al (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851–1857
Prenen H, De Schutter J, Jacobs B et al (2009) PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15:3184–3188
Benvenuti S, Frattini M, Arena S et al (2008) PIK3CAcancer mutations display gender and tissue specificity patterns. Hum Mutat 29:284–288
Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417
Sartore-Bianchi A, Moroni M, Veronese S et al (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238–3245
Rowinsky EK, Schwartz GH, Gollob JA et al (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cancer. J Clin Oncol 22:3003–3015
Weiner LM, Belldegrun AS, Crawford J et al (2008) Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14:502–508
Lynch TJJ, Kim ES, Eaby B et al (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610–621
Arends R, Yang B, Schwab G et al (2005) Flexible dosing schedules of panitumumab in cancer patients. J Clin Oncol 23, abstract 3089
Berlin J, Posex J, Tchekmedyian S et al (2007) Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 6:427–432
Hecht JR, Patnaik A, Berlin J et al (2007) Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110:980–988
Mitchell EP, Hecht JR, Baranda J et al (2007) Panitumumab activity in metastatic colorectal cancer (mCRC) petients (pts) with low or negative tumor epidermal growth factor receptor (EGFRr) levels: An updated analysis. J Clin Oncol 25, abstract 4082
Doi T, Ohtsu A, Tahara M et al (2009) Safety and pharmacokinetics of panitumumab in Japanase ptients with advanced solid tumors. Int J Clin Oncol 14:307–314
Kim R. Cetuximab and panitumumab: are they interchangeable? Lancet Oncol doi:10.1016/S1470-2045(09)70312-2
Douillard JS, Cassidy J, Tabermero J et al (2009) Randomized phase 3 study on panitutumab with FOLFOX4 compared to FOLFOX alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. Eur J Cancer Suppl 7:6
Peeters M, Price T, Hotko Y et al (2009) Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Eur J Cancer Suppl 7:2
Hecht JR, Mitchell E, Chidiac T et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672–680
Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563–572
Berlin J, Van Cutsem E, Peeters M et al (2007) Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials. J Clin Oncol 25(suppl) abstract 4134
Bencardino K, Ronzoni M, Manzoni M et al (2008) In vivo biological effects of Panitumumab plus chemotherapy in advanced colorectal cancer patients. J Clin Oncol 26, abstract 14576
Hendlisz A, Marechal R, Durbecq V et al (2008) Modulation and prognostic value of epidermal growth factor receptor expression in circulating tumor cells during chemotherapy in patients with metastatic colon cancer. J Clin Oncol 26, abstract 15038
Freeman DJ, Juan T, Reiner M et al (2008) Association of KRAS mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7:184–190
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kopper, L. Panitumumab: An Arrow on Target. Pathol. Oncol. Res. 16, 143–148 (2010). https://doi.org/10.1007/s12253-010-9257-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-010-9257-7